Key result
Cytarabine and daunorubicin induction chemotherapy caused early decreases in global longitudinal strain (P=0.01) and circumferential strain (P=0.011) in older AML patients, unlike clofarabine.
Why the study?
Data were lacking on changes in myocardial mechanics from standard of care low-dose anthracycline-based induction chemotherapy in older patients with AML.
Does cytarabine and daunorubicin chemotherapy cause early changes in myocardial strain compared to clofarabine in older patients with acute myeloid leukemia?
Cohort (n=32)
Does cytarabine and daunorubicin chemotherapy cause early changes in myocardial strain compared to clofarabine in older patients with acute myeloid leukemia?
p-value: p=0.01
Standard low-dose anthracycline-based induction chemotherapy causes early subclinical left ventricular dysfunction detectable by strain imaging in older AML patients, unlike clofarabine.
Authors
No takes yet. Share an insight, caveat, or question.
May signal early anthracycline cardiotoxicity in older AML; hypothesis-generating for strain monitoring, should not yet change practice.
Cascino et al. (2019) conducted a cohort in Acute myeloid leukemia (n=32). Cytarabine and daunorubicin vs. Clofarabine was evaluated on Average peak systolic global longitudinal and circumferential strain (p=0.01). Cytarabine and daunorubicin induction chemotherapy caused early decreases in global longitudinal strain (P=0.01) and circumferential strain (P=0.011) in older AML patients, unlike clofarabine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: